Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial

Rationale: Excessive daytime sleepiness in patients with obstructive sleep apnea is associated with substantial burden of illness. Objectives: To assess treatment effects of solriamfetol, a dopamine/norepinephrine reuptake inhibitor, on daily functioning, health-related quality of life, and work pro...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ann Am Thorac Soc
Autores principales: Weaver, Terri E., Drake, Christopher L., Benes, Heike, Stern, Thomas, Maynard, James, Thein, Stephen G., Andry, James M., Hudson, John D., Chen, Dan, Carter, Lawrence P., Bron, Morgan, Lee, Lawrence, Black, Jed, Bogan, Richard K.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Thoracic Society 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393785/
https://ncbi.nlm.nih.gov/pubmed/32353246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.202002-136OC
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares